Literature DB >> 25985046

Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.

Jeffrey R Vittengl1, Lee Anna Clark2, Michael E Thase3, Robin B Jarrett4.   

Abstract

After patients with major depressive disorder (MDD) respond to acute-phase cognitive therapy (CT), continuation-phase treatments may be applied to improve long-term outcomes. We clarified which CT responders experience remission, recovery, relapse, and recurrence by testing baseline demographic, clinical, and personality variables. The sample of CT responders at higher risk of relapse (N = 241) was randomized to 8 months of continuation-phase CT, double-blinded fluoxetine, or pill placebo, and followed 24 months (Jarrett & Thase, 2010). Patients with lower positive emotionality and behavioral activation at the end of acute-phase CT showed increased risk for relapse/recurrence of MDD. In addition, patients with lower positive emotionality and behavioral activation, as well as higher residual depression (including emotional, cognitive, and social facets), showed decreased probability of remission (≥6 continuous weeks of minimal or absent symptoms) after acute-phase CT. Finally, patients with greater residual depression, as well as younger age and earlier MDD onset, showed decreased probability of recovery (≥35 continuous weeks of minimal or absent symptoms) after acute-phase CT. Moderator analyses did not reveal differential prediction across the continuation phase treatment arms. These results may help clinicians gauge the prognoses and need for continuation treatment among MDD patients who respond to acute-phase CT. (c) 2015 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25985046      PMCID: PMC4438278          DOI: 10.1037/pst0000021

Source DB:  PubMed          Journal:  Psychotherapy (Chic)        ISSN: 0033-3204


  48 in total

Review 1.  Mediators and moderators of treatment effects in randomized clinical trials.

Authors:  Helena Chmura Kraemer; G Terence Wilson; Christopher G Fairburn; W Stewart Agras
Journal:  Arch Gen Psychiatry       Date:  2002-10

2.  Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.

Authors:  Robin B Jarrett; Michael E Thase
Journal:  Contemp Clin Trials       Date:  2010-05-06       Impact factor: 2.226

3.  Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.

Authors:  Robin B Jarrett; Abu Minhajuddin; Howard Gershenfeld; Edward S Friedman; Michael E Thase
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.

Authors:  Philip S Wang; Michael Lane; Mark Olfson; Harold A Pincus; Kenneth B Wells; Ronald C Kessler
Journal:  Arch Gen Psychiatry       Date:  2005-06

6.  Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Todd W Dunn; Robin B Jarrett
Journal:  J Consult Clin Psychol       Date:  2007-06

7.  Rebooting for Whom? Portfolios, Technology, and Personalized Intervention.

Authors:  Varda Shoham; Thomas R Insel
Journal:  Perspect Psychol Sci       Date:  2011-09

8.  Predictors of relapse in unipolar depressives: expressed emotion, marital distress, and perceived criticism.

Authors:  J M Hooley; J D Teasdale
Journal:  J Abnorm Psychol       Date:  1989-08

9.  The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.

Authors:  M B Keller; P W Lavori; B Friedman; E Nielsen; J Endicott; P McDonald-Scott; N C Andreasen
Journal:  Arch Gen Psychiatry       Date:  1987-06

10.  Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low.

Authors:  Scott B Patten
Journal:  BMC Psychiatry       Date:  2009-05-08       Impact factor: 3.630

View more
  8 in total

1.  Cognitive Therapy to Prevent Depressive Relapse in Adults.

Authors:  Jeffrey R Vittengl; Robin B Jarrett
Journal:  Curr Opin Psychol       Date:  2015-08-01

2.  Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  J Affect Disord       Date:  2016-04-13       Impact factor: 4.839

3.  Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Authors:  Boadie W Dunlop; Devon LoParo; Becky Kinkead; Tanja Mletzko-Crowe; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  Am J Psychiatry       Date:  2019-02-15       Impact factor: 18.112

4.  Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  Behav Res Ther       Date:  2016-08-18

5.  Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder.

Authors:  J R Vittengl; L A Clark; M E Thase; R B Jarrett
Journal:  Psychol Med       Date:  2015-06-22       Impact factor: 7.723

6.  Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  Psychiatry Res       Date:  2017-03-22       Impact factor: 3.222

7.  Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study.

Authors:  Jack D Edinger; Rachel Manber; Daniel J Buysse; Andrew D Krystal; Michael E Thase; Phillip Gehrman; Christopher P Fairholme; James Luther; Stephen Wisniewski
Journal:  J Clin Sleep Med       Date:  2017-02-15       Impact factor: 4.062

8.  Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review.

Authors:  P B Danborg; M Valdersdorf; P C Gøtzsche
Journal:  Int J Risk Saf Med       Date:  2019
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.